

Corresponding author(s):	Jiou Wang
Last updated by author(s):	Feb 5, 2019

Reporting Summary

X Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Sta	ntistics				
For	all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	The exact sam	ple size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
	A statement of	n whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
\boxtimes	A description	of all covariates tested			
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
\boxtimes	Estimates of e	ffect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated			
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Policy information about <u>availability of computer code</u>					
Data collection Leica application suite V4 software, Image Studio 2.0 (Li-Cor).		Leica application suite V4 software, Image Studio 2.0 (Li-Cor).			
Da	ita analysis	Excel, GraphPad Prism 6, MEGA7, ImageJ, IGV browser, SnpEff, SAMtools, Bowtie 2.			
	For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research <u>guidelines for submitting code & software</u> for further information.				
Data					
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets - A list of figures that have associated raw data - A description of any restrictions on data availability					
The following statement is included in the manuscript: "All data generated or analyzed during this study are included in this published article (and its supplementary information files)."					
Fie	eld-speci	fic reporting			

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

Life sciences study design

All studies must dis	sclose on these points even when the disclosure is negative.		
Sample size	Sample size for each experiment was noted in the Figure Legends. No statistical method was used to predetermine the sample size. The numbers of samples were determined by following standard practice in the field.		
Data exclusions	No exclusions. All the samples used in the statistical analyses were described in the Figure legends.		
Replication	The experiments were repeated in two or more independent trials. The results were consistent with the conclusions.		
Randomization	Samples or animals were randomly allocated into experimental groups based on their genotypes or different treatments as described in Figure Legends.		
Blinding	Data collection and analysis were not performed blind to the conditions of the experiments. In the experiments involving animals, individual animals were coded and behavioral data were collected in an unbiased manner. The molecular and cellular experiments were performed		

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods	
n/a Involved in the study	n/a Involved in the study	
Antibodies	ChIP-seq	
Eukaryotic cell lines	Flow cytometry	
Palaeontology	MRI-based neuroimaging	
Animals and other organisms		
Human research participants		
Clinical data		

following standard practice ensuring equal treatments of all samples.

Antibodies

Antibodies used

The antibodies used include the following: anti-SOD1-100 (Enzo, P00441, 1:3,000), anti-L3MBTL1 (Abcam, 1:500, and Genetex GTX103793, 1:100), anti-SETD8 (Cell Signaling Technology, C18B7, 1:1,000, and Genetex GTX119440, 1:1,000), anti-p53 7F5 (Cell Signaling Technology, #9282, 1:1,000), anti-C. elegans-SOD-1 (JH766, 1:5,000)58, anti-histone H4 (Active Motif, #61300, 1:1,000), anti-H4K20me1 (Active Motif, #39728, 1:1,000), anti-NeuN (Millipore, MAB377, 1:20), anti-YFP (Takara, #632381, 1:3,000), anti-beta-actin (Santa Cruz, sc- 47778B, 1:3,000), and anti-GAPDH (Thermo Fisher, TAB1001, 1:3,000). Secondary antibodies include goat anti-rabbit IgG IRDye, 1: 40,000 (680 LT, 926–68021 or 800 CW, 926–32211, LI-COR); donkey antimouse IgG, 1:40,000 (680 LT, 926–68022; or 800 CW, 926–32212, LI-COR); donkey anti-mouse IgG, 1:1,000 (Alexa Fluor 488, A-21202, ThermoFisher); and goat anti-rat IgG, 1:1,000 (Alexa Fluor 555, A-21434, ThermoFisher).

Validation

The information of the validated antibodies is available at the following websites:

C elegans SOD1: https://www.ncbi.nlm.nih.gov/pubmed/16234242

http://www.enzolifesciences.com/ADI-SOD-100/cu-zn-sod-polyclonal-antibody/

https://www.abcam.com/l3mbtl1-antibody-ab51880.html

https://www.genetex.com/Product/Detail/L3MBTL1-antibody/GTX103793

https://www.cellsignal.com/products/primary-antibodies/set8-c18b7-rabbit-mab/2996?

_=1549281172919&Ntt=C18B7&tahead=true

https://www.genetex.com/Product/Detail/SETD8-antibody/GTX119440

https://www.cellsignal.com/products/primary-antibodies/p53-antibody/9282

https://www.active motif.com/catalog/details/61299/histone-h4-antibody-pab-3

https://www.activemotif.com/catalog/details/39727/histone-h4-monomethyl-lys20-antibody-mab-clone-5e10-d8 http://www.emdmillipore.com/US/en/product/Anti-NeuN-Antibody-clone-A60,MM_NF-MAB377?ReferrerURL=https%3A%2F%

2Fwww.google.com%2F

https://www.takarabio.com/products/antibodies-and-elisa/fluorescent-protein-antibodies/green-fluorescent-protein-antibodies? and the second products of the second protein-antibodies of the second products of the second p

https://www.scbt.com/scbt/product/beta-actin-antibody-c4?productCanUrl=beta-actin-antibody-c4&_requestid=1024537

https://www.thermofisher.com/antibody/product/GAPDH-Antibody-Polyclonal/TAB1001

https://www.licor.com/bio/products/reagents/secondary_antibodies/irdye_680lt.html

https://www.licor.com/bio/products/reagents/secondary_antibodies/irdye_800cw.html

https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-

Polyclonal/A-21202

https://www.thermofisher.com/antibody/product/Goat-anti-Rat-lgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21434

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s) MEFs, HEK293 cells were from ATCC.

Mouse embryonic stem cell line RW4 (from Dr. Shelly E. Sakiyama-Elbert, Washington University School of Medicine, St.

Louis, MO). Rat primary neurons were derived from animals in this study.

Authentication RW4 was authenticated by their ability to differentiate into motor-neurons, and resistance to puromycin. MEFs were

confirmed by their distinctive morphology and growth properties.

Mycoplasma contamination Not tested

yespiasina sentanimation

Commonly misidentified lines (See <u>ICLAC</u> register)

None

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals The animals used in this study include the SOD1G93A line [B6.Cg-Tg(SOD1*G93A)1Gur/J; Jackson Laboratory, stock 004435] (5

weeks to 6 months old), the SOD1G85R-YFP (10-15 months old) and SOD1WT-YFP lines (9-15 months old) (Ref. #26), and C57BL/6J mice (Jackson Laboratory, stock (5 weeks to 10 months old). Both males and females were used as specified in the study. The ages of the animals depends on specific experiments as described and the age of disease onset as previously

reported.

Wild animals The study did not involve wild animals.

Field-collected samples The study did not involve samples collected from the field.

Ethics oversight The animal protocol was approved by the Animal Care and Use Committee of the Johns Hopkins Medical Institutions.

Note that full information on the approval of the study protocol must also be provided in the manuscript.